The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study

Outcomes from the Acute and Continuation Phases

Martin B. Keller, Madhukar H. Trivedi, Michael E. Thase, Richard C. Shelton, Susan G. Kornstein, Charles B. Nemeroff, Edward S. Friedman, Alan J. Gelenberg, James H. Kocsis, David L. Dunner, Boadie W. Dunlop, Robert M. Hirschfeld, Anthony J. Rothschild, James M. Ferguson, Alan F. Schatzberg, John M. Zajecka, Ron Pedersen, Bing Yan, Saeeduddin Ahmed, Michael Schmidt & 1 others Philip T. Ninan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment. Methods: In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75-300 mg/day; n = 821) or fluoxetine (20-60 mg/day; n = 275). After a 10-week acute treatment phase, responders entered a 6-month continuation phase of ongoing therapy with double-blind venlafaxine ER (n = 530) or fluoxetine (n = 185). In the acute phase, the primary outcome was response, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score ≤12 or ≥50% decrease from baseline; the secondary outcome was remission, defined as a HDRS score ≤7. In the continuation phase, the primary outcome was the proportion of patients who sustained response or remission. Secondary measures included time to onset of sustained response or remission (i.e., meeting criteria at two or more consecutive visits), relapse rates, and quality-of-life measures. Results: At the acute treatment phase end point, response rates were 79% for both venlafaxine ER and fluoxetine; remission rates were 49% and 50% for venlafaxine ER and fluoxetine, respectively. In the continuation phase, response rates were 90% and 92%, and remission rates were 72% and 69% for venlafaxine ER and fluoxetine, respectively. Rates of sustained remission at the end of the continuation phase were 52% and 58% for venlafaxine ER and fluoxetine, respectively. Conclusion: Venlafaxine ER and fluoxetine were comparably effective during both acute and continuation phase therapy.

Original languageEnglish (US)
Pages (from-to)1371-1379
Number of pages9
JournalBiological Psychiatry
Volume62
Issue number12
DOIs
StatePublished - Dec 15 2007

Fingerprint

Fluoxetine
Outcome Assessment (Health Care)
Depression
Therapeutics
Venlafaxine Hydrochloride
Depressive Disorder
Double-Blind Method
Outpatients
Quality of Life
Safety
Recurrence

Keywords

  • Acute therapy
  • antidepressants
  • continuation therapy
  • fluoxetine
  • major depression
  • venlafaxine ER

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., ... Ninan, P. T. (2007). The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. Biological Psychiatry, 62(12), 1371-1379. https://doi.org/10.1016/j.biopsych.2007.04.040

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study : Outcomes from the Acute and Continuation Phases. / Keller, Martin B.; Trivedi, Madhukar H.; Thase, Michael E.; Shelton, Richard C.; Kornstein, Susan G.; Nemeroff, Charles B.; Friedman, Edward S.; Gelenberg, Alan J.; Kocsis, James H.; Dunner, David L.; Dunlop, Boadie W.; Hirschfeld, Robert M.; Rothschild, Anthony J.; Ferguson, James M.; Schatzberg, Alan F.; Zajecka, John M.; Pedersen, Ron; Yan, Bing; Ahmed, Saeeduddin; Schmidt, Michael; Ninan, Philip T.

In: Biological Psychiatry, Vol. 62, No. 12, 15.12.2007, p. 1371-1379.

Research output: Contribution to journalArticle

Keller, MB, Trivedi, MH, Thase, ME, Shelton, RC, Kornstein, SG, Nemeroff, CB, Friedman, ES, Gelenberg, AJ, Kocsis, JH, Dunner, DL, Dunlop, BW, Hirschfeld, RM, Rothschild, AJ, Ferguson, JM, Schatzberg, AF, Zajecka, JM, Pedersen, R, Yan, B, Ahmed, S, Schmidt, M & Ninan, PT 2007, 'The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases', Biological Psychiatry, vol. 62, no. 12, pp. 1371-1379. https://doi.org/10.1016/j.biopsych.2007.04.040
Keller, Martin B. ; Trivedi, Madhukar H. ; Thase, Michael E. ; Shelton, Richard C. ; Kornstein, Susan G. ; Nemeroff, Charles B. ; Friedman, Edward S. ; Gelenberg, Alan J. ; Kocsis, James H. ; Dunner, David L. ; Dunlop, Boadie W. ; Hirschfeld, Robert M. ; Rothschild, Anthony J. ; Ferguson, James M. ; Schatzberg, Alan F. ; Zajecka, John M. ; Pedersen, Ron ; Yan, Bing ; Ahmed, Saeeduddin ; Schmidt, Michael ; Ninan, Philip T. / The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study : Outcomes from the Acute and Continuation Phases. In: Biological Psychiatry. 2007 ; Vol. 62, No. 12. pp. 1371-1379.
@article{d24b59622b7847de8b05d990ae67e8bf,
title = "The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases",
abstract = "Background: We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment. Methods: In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75-300 mg/day; n = 821) or fluoxetine (20-60 mg/day; n = 275). After a 10-week acute treatment phase, responders entered a 6-month continuation phase of ongoing therapy with double-blind venlafaxine ER (n = 530) or fluoxetine (n = 185). In the acute phase, the primary outcome was response, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score ≤12 or ≥50{\%} decrease from baseline; the secondary outcome was remission, defined as a HDRS score ≤7. In the continuation phase, the primary outcome was the proportion of patients who sustained response or remission. Secondary measures included time to onset of sustained response or remission (i.e., meeting criteria at two or more consecutive visits), relapse rates, and quality-of-life measures. Results: At the acute treatment phase end point, response rates were 79{\%} for both venlafaxine ER and fluoxetine; remission rates were 49{\%} and 50{\%} for venlafaxine ER and fluoxetine, respectively. In the continuation phase, response rates were 90{\%} and 92{\%}, and remission rates were 72{\%} and 69{\%} for venlafaxine ER and fluoxetine, respectively. Rates of sustained remission at the end of the continuation phase were 52{\%} and 58{\%} for venlafaxine ER and fluoxetine, respectively. Conclusion: Venlafaxine ER and fluoxetine were comparably effective during both acute and continuation phase therapy.",
keywords = "Acute therapy, antidepressants, continuation therapy, fluoxetine, major depression, venlafaxine ER",
author = "Keller, {Martin B.} and Trivedi, {Madhukar H.} and Thase, {Michael E.} and Shelton, {Richard C.} and Kornstein, {Susan G.} and Nemeroff, {Charles B.} and Friedman, {Edward S.} and Gelenberg, {Alan J.} and Kocsis, {James H.} and Dunner, {David L.} and Dunlop, {Boadie W.} and Hirschfeld, {Robert M.} and Rothschild, {Anthony J.} and Ferguson, {James M.} and Schatzberg, {Alan F.} and Zajecka, {John M.} and Ron Pedersen and Bing Yan and Saeeduddin Ahmed and Michael Schmidt and Ninan, {Philip T.}",
year = "2007",
month = "12",
day = "15",
doi = "10.1016/j.biopsych.2007.04.040",
language = "English (US)",
volume = "62",
pages = "1371--1379",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study

T2 - Outcomes from the Acute and Continuation Phases

AU - Keller, Martin B.

AU - Trivedi, Madhukar H.

AU - Thase, Michael E.

AU - Shelton, Richard C.

AU - Kornstein, Susan G.

AU - Nemeroff, Charles B.

AU - Friedman, Edward S.

AU - Gelenberg, Alan J.

AU - Kocsis, James H.

AU - Dunner, David L.

AU - Dunlop, Boadie W.

AU - Hirschfeld, Robert M.

AU - Rothschild, Anthony J.

AU - Ferguson, James M.

AU - Schatzberg, Alan F.

AU - Zajecka, John M.

AU - Pedersen, Ron

AU - Yan, Bing

AU - Ahmed, Saeeduddin

AU - Schmidt, Michael

AU - Ninan, Philip T.

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Background: We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment. Methods: In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75-300 mg/day; n = 821) or fluoxetine (20-60 mg/day; n = 275). After a 10-week acute treatment phase, responders entered a 6-month continuation phase of ongoing therapy with double-blind venlafaxine ER (n = 530) or fluoxetine (n = 185). In the acute phase, the primary outcome was response, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score ≤12 or ≥50% decrease from baseline; the secondary outcome was remission, defined as a HDRS score ≤7. In the continuation phase, the primary outcome was the proportion of patients who sustained response or remission. Secondary measures included time to onset of sustained response or remission (i.e., meeting criteria at two or more consecutive visits), relapse rates, and quality-of-life measures. Results: At the acute treatment phase end point, response rates were 79% for both venlafaxine ER and fluoxetine; remission rates were 49% and 50% for venlafaxine ER and fluoxetine, respectively. In the continuation phase, response rates were 90% and 92%, and remission rates were 72% and 69% for venlafaxine ER and fluoxetine, respectively. Rates of sustained remission at the end of the continuation phase were 52% and 58% for venlafaxine ER and fluoxetine, respectively. Conclusion: Venlafaxine ER and fluoxetine were comparably effective during both acute and continuation phase therapy.

AB - Background: We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment. Methods: In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75-300 mg/day; n = 821) or fluoxetine (20-60 mg/day; n = 275). After a 10-week acute treatment phase, responders entered a 6-month continuation phase of ongoing therapy with double-blind venlafaxine ER (n = 530) or fluoxetine (n = 185). In the acute phase, the primary outcome was response, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score ≤12 or ≥50% decrease from baseline; the secondary outcome was remission, defined as a HDRS score ≤7. In the continuation phase, the primary outcome was the proportion of patients who sustained response or remission. Secondary measures included time to onset of sustained response or remission (i.e., meeting criteria at two or more consecutive visits), relapse rates, and quality-of-life measures. Results: At the acute treatment phase end point, response rates were 79% for both venlafaxine ER and fluoxetine; remission rates were 49% and 50% for venlafaxine ER and fluoxetine, respectively. In the continuation phase, response rates were 90% and 92%, and remission rates were 72% and 69% for venlafaxine ER and fluoxetine, respectively. Rates of sustained remission at the end of the continuation phase were 52% and 58% for venlafaxine ER and fluoxetine, respectively. Conclusion: Venlafaxine ER and fluoxetine were comparably effective during both acute and continuation phase therapy.

KW - Acute therapy

KW - antidepressants

KW - continuation therapy

KW - fluoxetine

KW - major depression

KW - venlafaxine ER

UR - http://www.scopus.com/inward/record.url?scp=36549069307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549069307&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2007.04.040

DO - 10.1016/j.biopsych.2007.04.040

M3 - Article

VL - 62

SP - 1371

EP - 1379

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 12

ER -